Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00197080 · ClinicalTrials.gov registry record · Phase 3
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT00197080 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 380 participants.
The verdict
NCT00197080, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).
Interventions
- DRUG Ropinirole Extended Release (XR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00197080
The ClinicalTrials.gov registry entry for NCT00197080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ropinirole Extended Release (XR) is the first listed.
NCT00197080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00197080 about?
NCT00197080 is a clinical study titled "Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome". The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).
What is the current status of trial NCT00197080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2005-06. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00197080?
The interventions under investigation include: Ropinirole Extended Release (XR) (DRUG).
Who is sponsoring clinical trial NCT00197080?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.